Skip to content

Ablation of Consecutive Atrial Tachycardia

Ablation of CONseCutive atriaL Tachycardia gUided by Ultra-high-DEnsity Mapping

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05239364
Acronym
CONCLUDE
Enrollment
100
Registered
2022-02-14
Start date
2020-12-22
Completion date
2027-06-01
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmias, Cardiac, Atrial Tachycardia, Heart Arrhythmia, Heart Diseases

Keywords

Atrial fibrillation, Atrial tachycardia, Pulmonary vein isolation, Electroanatomical mapping, High density mapping

Brief summary

Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.

Interventions

PROCEDURECatheter ablation

Catheter-based ablation of arrhythmias using radiofrequency.

Sponsors

Evangelical Hospital Düsseldorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery * Surface ECG-documentation of AT as primary clinical arrhythmia * ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms

Exclusion criteria

* \< 18 years * No previous atrial fibrillation ablation procedure or cardiac surgery * Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment * History of hemorrhagic diathesis or other coagulopathies * Contraindications for oral anticoagulation * Hyper- or hypothyroidism * Has any condition that would make participation not be in the best interest of the subject

Design outcomes

Primary

MeasureTime frame
Recurrence of any sustained arrhythmia (>30 sec.)1 year

Secondary

MeasureTime frameDescription
Inducibility of atrial tachycardia (AT) after ablation of clinical/primary AT (partial success)IntraproceduralCategorical variable (yes/no)
Predictability of secondary AT by analysis of clinical AT map and voltage mapIntraprocedural
Procedure duration timeIntraprocedural
Fluoroscopy timeintraprocedural
Total radiofrequency application timeintraprocedural
Ablated area (cm2)intraprocedural
Number of blocked linesintraprocedural
Area of low voltage in sinus map (cm2)Intraprocedural

Countries

Germany

Contacts

CONTACTChristian Meyer, MD
christian.meyer@evk-duesseldorf.de00492119191855
PRINCIPAL_INVESTIGATORChristian Meyer, MD

Evangelic Hospital Düsseldorf

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026